Clinical and Molecular Characteristics of EGFR Mutant Lung Cancers with Concurrent TP53 and RB1 Mutations

被引：0

作者：

Offin, M. ^{[1
]}

Tenet, M. ^{[1
]}

Shen, R. ^{[2
]}

Rekhtman, N. ^{[3
]}

Rizvi, H. ^{[1
]}

Hellmann, M. ^{[1
]}

Arcila, M. ^{[4
]}

Ladanyi, M. ^{[5
]}

Rudin, C. ^{[1
]}

Kris, M. ^{[1
]}

Yu, H. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Med Oncol, 1275 York Ave, New York, NY 10021 USA

[2] Mem Sloan Kettering Canc Ctr, Epidemiol & Biostat, 1275 York Ave, New York, NY 10021 USA

[3] Mem Sloan Kettering Canc Ctr, Pathol, 1275 York Ave, New York, NY 10021 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Pathol Mol Diagnost, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期

关键词：

Small cell lung cancer transformation; EGFR-mutant lung cancer; Lineage Plasticity;

D O I：

10.1016/j.jtho.2018.08.450

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA16.04

引用

页码：S412 / S412

页数：1

共 50 条

[1] Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes
Offin, Michael
Chan, Joseph M.
Tenet, Megan
Rizvi, Hira A.
Shen, Ronglai
Riely, Gregory J.
Rekhtman, Natasha
Daneshbod, Yahya
Quintanal-Villalonga, Alvaro
Penson, Alexander
Hellmann, Matthew D.
Arcila, Maria E.
Ladanyi, Marc
Pe'er, Dana
Kris, Mark G.
Rudin, Charles M.
Yu, Helena A.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : 1784 - 1793
[2] Genetic Characteristics of EGFR Concurrent Variants with RB1 and TP53 in NCSLC Patients
Chen, H.
Yuan, S.
Chen, L.
Shi, X.
Wang, L.
Dong, X.
Wang, M.
Wang, A.
Liu, W.
Cui, Z.
Chen, C.
Mei, L.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S587 - S588
[3] Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations.
Wang, Jun
Chen, Gang
Zhang, Bicheng
Sun, Jianguo
Liang, Jing
Liu, Xiaolin
Li, Yan
Wang, Baocheng
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Osimertinib, platinum, etoposide as initial treatment for patients with EGFR mutant lung cancers with TP53 and RB1 alterations.
Chen, Monica F.
Rakhade, Swanand
Quintanal-Villalonga, Alvaro
Lee, Jake
Forsythe, Britney
Moses, Khadeja A.
Ahn, Linda Su Hyun
Pupo, Amanda
Falcon, Christina J.
Rekhtman, Natasha
Kris, Mark G.
Rudin, Charles M.
Chan, Joseph Minhow
Yu, Helena Alexandra
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[5] Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy
Lu, Yiyu
Li, Zhihua
Zhu, Huawei
Zhao, Juan
Xu, Mian
Gu, Weiguang
[J]. ANNALS OF PALLIATIVE MEDICINE, 2021, 10 (12) : 12886 - 12893
[6] Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
Huang, J.
Huang, W.
Wang, Q.
Zhang, C.
Ni, S.
Sun, D.
Zhou, Y.
Hou, T.
Sun, W.
Chen, Z.
Wu, Y. -L.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S48 - S48
[7] Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma
Vokes, Natalie, I
Chambers, Emily
Nguyen, Tom
Coolidge, Alexis
Lydon, Christine A.
Le, Xiuning
Sholl, Lynette
Heymach, John, V
Nishino, Mizuki
Van Allen, Eliezer M.
Janne, Pasi A.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (06) : 779 - 792
[8] Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas
Watanabe, T
Yokoo, H
Yokoo, M
Yonekawa, Y
Kleihues, P
Ohgaki, H
[J]. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2001, 60 (12): : 1181 - 1189
[9] Smoking, lung cancers and their TP53 mutations
Cooper, CS
[J]. MUTAGENESIS, 2002, 17 (04) : 279 - 280
[10] Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma
Qian, Huiwen
Hou, Chunqi
Zhang, Yi
Ji, Shundong
Zhong, Chongke
Li, Juan
Zhang, Qianqian
Huang, Jianan
Li, Chong
Ji, Cheng
[J]. CANCER GENETICS, 2023, 278 : 62 - 70

← 1 2 3 4 5 →